ARCHIMED has acquired Esperion for $1.1 billion. Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therapies. The company leverages deep domain expertise in ACLY biology to develop and commercialize transformative medicines for patients worldwide. Esperion currently markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels and are at risk of cardiovascular disease.
Esperion possesses a broad U.S. commercial infrastructure and has secured global approvals across more than 40 countries. This robust positioning has enabled Esperion to serve as a partner-of-choice for global innovators seeking U.S. market access through various avenues, including in-license, co-promotion, and revenue share opportunities. In parallel, the company is actively advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases.
This acquisition by ARCHIMED for $1.1 billion is strategically significant, integrating Esperion's established commercial presence, product portfolio, and scientific expertise into the acquiring entity. The transaction is expected to enhance the market reach of Esperion's existing cardiometabolic therapies and accelerate the development of its promising pipeline assets. Synergies are anticipated through leveraging Esperion's global footprint and deep domain knowledge, supported by ARCHIMED's strategic oversight to drive further market penetration and innovation.
The combined entity is poised to strengthen its position within the cardiometabolic and rare disease sectors. This acquisition aims to ensure continued investment in Esperion's innovative therapies and expand their availability to patients globally, fostering sustained growth and impact in critical therapeutic areas for patient benefit.